EP1663272A1 - Alkaloid-reduced kava extract - Google Patents

Alkaloid-reduced kava extract

Info

Publication number
EP1663272A1
EP1663272A1 EP04786236A EP04786236A EP1663272A1 EP 1663272 A1 EP1663272 A1 EP 1663272A1 EP 04786236 A EP04786236 A EP 04786236A EP 04786236 A EP04786236 A EP 04786236A EP 1663272 A1 EP1663272 A1 EP 1663272A1
Authority
EP
European Patent Office
Prior art keywords
extract
kava
organic
treatment
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04786236A
Other languages
German (de)
French (fr)
Inventor
Wilhelm Berkulin
Björn FEISTEL
Frauke Gaedcke
Ivo Pischel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finzelberg GmbH and Co KG
Original Assignee
Finzelberg GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finzelberg GmbH and Co KG filed Critical Finzelberg GmbH and Co KG
Priority to EP04786236A priority Critical patent/EP1663272A1/en
Publication of EP1663272A1 publication Critical patent/EP1663272A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/67Piperaceae (Pepper family), e.g. Jamaican pepper or kava

Definitions

  • the present invention relates to a process for the production of a plant extract of kava (Piper methysticum), an extract obtainable according to the process according to the invention and the use of the extract.
  • Kava kava also known as intoxicant (Piper methysticum FORSTER, Piperaceae), is a close relative of black pepper and is native to Polynesia and Melanesia.
  • intoxicant Pier methysticum FORSTER, Piperaceae
  • the perennial shrub with 30 cm large, heart-shaped leaves grows to a height of approx. 3 m and forms a strong rhizome of up to 10 kg in 5 to 6 years.
  • the most important growers are Samoa and Fiji, where the propagation takes place exclusively via cuttings.
  • Kava-kava (also kawa-kawa) was distributed millennia ago by seafaring peoples on the Pacific Islands, for whom the roots of the psychoactive pepper variety were of great importance in cultural and religious life. The toning, refreshing drink was indispensable in daily use and at ceremonies all over Polynesia. It was also used in folk medicine.
  • lactones identified as ingredients have been clinically proven. They have a calming, antispasmodic, local anesthetic and muscle relaxant effect. However, they also show neurophysiological activity, which e.g. demonstrated in an improvement in sleep [Piscopo G; Alt Med Rev 1997; 2 (5): 355-364].
  • German and other western doctors have been successfully using kava-kava for years to treat anxiety and restlessness as a natural phyto-tranquilizer with few side effects.
  • the peeled, cut rhizome dried or fresh is used.
  • the roots were traditionally chewed for crushing. Extracts are now commercially available worldwide.
  • the main substances of kava-kava are approx. 15 compounds, chemical active substances known as cavaprone, with the largest proportions of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one) and make up its methoxy and dihydro derivatives Yangonin and Marindinin.
  • the process according to the invention for producing a plant extract of kava has the following steps:
  • organic extraction agents such as water-containing or anhydrous free alcohols, in particular alcohols, ketones, carboxylic esters, alkanes, chlorinated hydrocarbons and supercritical gases or mixtures thereof containing 1 to 3 carbon atoms, and also
  • the process according to the invention leads to a plant extract which is practically freed from alkaloid compounds.
  • the invention advantageously contains Extract of kava (Piper methysticum), obtainable according to the present invention, contains the majority of the naturally occurring kavapyrones in the kava plant.
  • leaves, stem bark or rhizome can be used as plant parts, fresh or dried.
  • the organic extractant is in particular methanol, ethanol, propanol, acetone, ethyl acetate or mixtures thereof with water, dichloromethane and / or supercritical carbon dioxide.
  • the treatment under basic or acidic conditions is carried out in particular using sodium hydroxide and lime liquor or using mineral acids such as sulfuric acid or hydrochloric acid. This treatment advantageously leads to the depletion of alkaloids.
  • Said treatment under basic or acidic conditions is preferably carried out under conditions in which the water content is more than 50% by volume, preferably more than 70% by volume, of the solution.
  • the pH should be 9 or more, preferably 10 or more. In one embodiment of the invention, the pH can also be 11 or more. Particularly suitable ranges are pH 9 to 11.
  • the pH should preferably be 3 or less, preferably 2.5 or less. In a preferred embodiment, it can also be 2 or less. Particularly suitable ranges are pH 3 to pH 1.5.
  • the treatment is typically carried out for a period of 5 minutes to 12 hours, more preferably between 0.5 and 6 hours, even more preferably between 1 and 4 hours.
  • the treatment can also be carried out at a somewhat elevated temperature.
  • Particularly suitable conditions for the treatment are temperatures between 0 and 80 ° C, more preferably between room temperature and 50 ° C.
  • Alkaloids and / or other substances can also be separated off by adsorption processes on adsorbents, for example on cation exchangers or organic polymer resins (for example Amberlite XAD). Liquid-liquid extraction is also an alternative or additional step.
  • the extract is extracted in aqueous solution with an organic solvent.
  • suitable solvents are butanol and ethyl acetate.
  • depletion steps can of course not only be carried out individually, but also in combination and in any order.
  • a suitable method is, for example, treatment with a cation exchanger in acid (H + ) form. This simultaneously lowers the pH and also enables adsorption on cation exchangers.
  • the invention also relates to a plant extract obtainable by the process according to the invention.
  • the extracts according to the invention contain the kavapyrones, which are mostly chemical derivatives of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one).
  • the effect of the method according to the invention may be based on the chemically relatively reduced stability of the alkaloids, which seem to be very susceptible to hydrolysis of the constituents to be structurally regarded as amide alkaloids.
  • This decomposition can be forced, for example, by basic or acidic saponification.
  • an amino and an acid component are released from the alkaloids, which should be less harmful or can be eliminated by suitable adsorbers, such as ion exchangers.
  • alkaloids With regard to the physical instability of the alkaloids, thermal lability was observed, especially in the presence of water, which is probably also manifested solvatolytically. Furthermore, the above-mentioned alkaloids, like their hydrolysis products, can have a basic or amphoteric character. Strong affinity for charged adsorbents was found. Such adsorbers are also very suitable hydrolysis catalysts and therefore preferred media for separating the alkaloid traces.
  • the extract according to the invention can be used for the production of medicaments, food supplements, veterinary products or cosmetics in liquid or solid extract preparations.
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. The mixture is then stirred at 55 ° C. Product temperature, so much sulfuric acid added dropwise until a pH of approx. 3 is reached. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are filtered off and the extract solution is evaporated down again to the spissumin extract.
  • the spissum contains 54% by weight Kavapyrone (HPLC) and 5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at room temperature, as much lime is added dropwise until a pH of approx. 11 is reached. After stirring for 2 hours, the extract solution is neutralized with a mineral acid solution. Precipitated precipitates are separated and the extract solution is evaporated again to the spissum extract.
  • the spissum contains 49% by weight Kavapyrone (HPLC) and ⁇ 5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at 55 ° C product temperature, so much sulfuric acid is added dropwise until a pH of approx. 3 is established. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are separated and the extract solution is converted into an organic phase by stirring twice with the same volume of ethyl acetate. This is evaporated under reduced pressure.
  • the spissum obtained contains 62% by weight of Kavapyrone (HPLC) and ⁇ 5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 2 100 g of the kava spissum extract obtained according to Example 2 are suspended in sulfuric acid water at pH 1-2 with vigorous stirring at 40 ° C. for 1 h. The aqueous phase that separates is then removed. The extract is redissolved in ethanol 80% (V / V) and passed over a cation exchanger. The continuous aqueous-ethanolic eluates are then evaporated under reduced pressure.
  • the spissum obtained contains 47% by weight of Kavapyrone (HPLC) and ⁇ 5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • the extract is redissolved in 70% v / v ethanol and passed through a strongly acidic cation exchanger (sulfonic acid resin) in the form of a packed column.
  • the eluate obtained after passage through the column is evaporated in vacuo to spissum at 55 ° C.
  • This extract still contains a high proportion of 52% by weight of kavapyrones and is practically free of alkaloid compounds ( ⁇ 5 ppm), based in each case on the dry extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a method for producing a plant extract from Kava (Piper methysticum), comprising the following steps: extracting plant parts by using organic extractants such as water-containing or water-free alcohols, ketones, carboxylic acids, alkanes, chlorohydrocarbons and supercritical gases or mixtures thereof, and treating the residue which is at least partially liberated from the organic extractant under acidic (pH = 3) or basic (pH = 9) conditions, and/or subjecting the residue to adsorption processes on cation exchangers or uncharged adsorbents based on organic polymer resins.

Description

Alkaloid-reduzierter Kava -Extrakt Alkaloid reduced kava extract
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines Pflanzenextraktes von Kava (Piper methysticum), einen Extrakt erhältlich gemäß dem erfindungsgemäßen Verfahren sowie die Verwendung des Extraktes.The present invention relates to a process for the production of a plant extract of kava (Piper methysticum), an extract obtainable according to the process according to the invention and the use of the extract.
Kava-Kava, auch Rauschpfeffer (Piper methysticum FORSTER, Piperaceae) genannt, ist ein naher Verwandter des Schwarzen Pfeffers und in Polynesien und Melanesien heimisch. Dort unterscheidet man zahlreiche morphologische und chemische Typen bzw. Varietäten. Der ausdauernde Strauch mit 30 cm großen, herzförmigen Blättern, wird ca. 3 m hoch und bildet in 5 bis 6 Jahren einen kräftigen Wurzelstock von bis zu 10 kg Gewicht aus. Wichtigste Anbauender sind Samoa und Fiji, wobei die Vermehrung ausschließlich über Stecklinge erfolgt.Kava kava, also known as intoxicant (Piper methysticum FORSTER, Piperaceae), is a close relative of black pepper and is native to Polynesia and Melanesia. A distinction is made between numerous morphological and chemical types or varieties. The perennial shrub with 30 cm large, heart-shaped leaves grows to a height of approx. 3 m and forms a strong rhizome of up to 10 kg in 5 to 6 years. The most important growers are Samoa and Fiji, where the propagation takes place exclusively via cuttings.
Kava-Kava (auch Kawa-Kawa) wurde bereits vor Jahrtausenden durch seefahrende Völker auf den Pazifischen Inseln verbreitet, für die die Wurzeln der psychoaktiven Pfefferart im kulturellen und religiösen Leben eine große Bedeutung hatten. Im täglichen Gebrauch und bei Zeremonien überall in Polynesien war das tonisierende, erfrischende Getränk unverzichtbar. Es fand auch volksmedizinische Verwendung.Kava-kava (also kawa-kawa) was distributed millennia ago by seafaring peoples on the Pacific Islands, for whom the roots of the psychoactive pepper variety were of great importance in cultural and religious life. The toning, refreshing drink was indispensable in daily use and at ceremonies all over Polynesia. It was also used in folk medicine.
Verschiedene pharmakologische Aktivitäten der als Inhaltsstoffe identifizierten Lactone sind klinisch belegt. So wirken sie beruhigend, krampflösend, lokal- anästhetisch und muskelentspannend. Sie zeigen aber auch neurophysiologi- sche Aktivität, was sich z.B. in einer Verbesserung des Schlafes demonstriert [Piscopo G; Alt Med Rev 1997; 2(5): 355-364].Various pharmacological activities of the lactones identified as ingredients have been clinically proven. They have a calming, antispasmodic, local anesthetic and muscle relaxant effect. However, they also show neurophysiological activity, which e.g. demonstrated in an improvement in sleep [Piscopo G; Alt Med Rev 1997; 2 (5): 355-364].
Von deutschen und anderen westlichen Medizinern wird Kava-Kava seit Jahren erfolgreich zur Behandlung von Angst- und Unruhezuständen als natürlicher und nebenwirkungsarmer Phyto-Tranquilizer angewendet.German and other western doctors have been successfully using kava-kava for years to treat anxiety and restlessness as a natural phyto-tranquilizer with few side effects.
Das geschälte, geschnittene Rhizom getrocknet oder frisch findet Verwendung. Hierbei wurden traditionell die Wurzeln zur Zerkleinerung vorgekaut. Heute sind weltweit Extrakte im Handel. Die Hauptsubstanzen von Kava-Kava stellen ca. 15 Verbindungen, als Kavapy- rone bezeichnete chemische Wirkstoffe, dar, wobei die größten Anteile Kavain (5,6-Dihydroxy-4-methoxy-6-styryl-2H-pyran-2-on) und dessen Methoxy- und Dihydroderivaten Yangonin und Marindinin ausmachen.The peeled, cut rhizome dried or fresh is used. The roots were traditionally chewed for crushing. Extracts are now commercially available worldwide. The main substances of kava-kava are approx. 15 compounds, chemical active substances known as cavaprone, with the largest proportions of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one) and make up its methoxy and dihydro derivatives Yangonin and Marindinin.
Allerdings wurde auf Grund von leberschädigenden Nebenwirkungen die Anwendung von Kava Kava Extrakten fragwürdig oder sogar behördlich verhindert.However, due to liver-damaging side effects, the use of kava kava extracts was questionably or even officially prevented.
Der Art der Gewinnung der Extrakte kommt große Bedeutung zu, da es durch die Extraktionsbedingungen zur Anreicherung von toxischen Substanzen kommen kann. Ein der Erfindung zu Grunde liegendes technisches Problem ist mithin die Bereitstellung eines Verfahren zur Gewinnung von Kava-Kava Extrakten mit geringem Nebenwirkungspotential.The way in which the extracts are obtained is of great importance since the extraction conditions can lead to the accumulation of toxic substances. A technical problem on which the invention is based is therefore the provision of a method for obtaining kava-kava extracts with low potential for side effects.
Überraschenderweise wurde gefunden, daß dieses Problem durch geringen technischen Aufwand während oder als zusätzlicher Schritt zu der konventio- nellen Kava-Extraktherstellung gelöst werden kann.Surprisingly, it was found that this problem can be solved by little technical effort during or as an additional step to the conventional kava extract production.
Das erfindungsgemäße Verfahren zur Herstellung eines Pflanzenextraktes von Kava (Piper methysticum) weist die folgenden Schritten auf:The process according to the invention for producing a plant extract of kava (Piper methysticum) has the following steps:
- Extraktion von Pflanzenteilen mit organischen Extraktionsmitteln wie wasserhaltigen oder wasserfreien freien Alkoholen, insbesondere 1 bis 3 Koh- lenstoffatome enthaltende Alkohole, Ketonen, Carbonsäureestern, Alkanen, chlorierten Kohlenwasserstoffen sowie überkritischen Gasen oder Gemischen daraus, sowie- Extraction of parts of plants with organic extraction agents such as water-containing or anhydrous free alcohols, in particular alcohols, ketones, carboxylic esters, alkanes, chlorinated hydrocarbons and supercritical gases or mixtures thereof containing 1 to 3 carbon atoms, and also
- Behandlung des von organischen Extraktionsmitteln zumindest teilweise befreiten Rückstandes unter sauren oder basischen Bedingungen und/oder- Treatment of the residue at least partially freed from organic extracting agents under acidic or basic conditions and / or
- Adsorptionsprozessen an geladenen oder ungeladenen Adsorbentien.- Adsorption processes on charged or uncharged adsorbents.
Das erfindungsgemäße Verfahren führt zu einem Pflanzenextrakt, der praktisch von Alkaloidverbindungen befreit ist. Vorteilhafterweise enthält der erfin- dungsgemäß erhältliche Extrakt von Kava (Piper methysticum) den größten Teil der in der Kavapflanze natürlich vorhandenen Kavapyrone.The process according to the invention leads to a plant extract which is practically freed from alkaloid compounds. The invention advantageously contains Extract of kava (Piper methysticum), obtainable according to the present invention, contains the majority of the naturally occurring kavapyrones in the kava plant.
Erfindungsgemäß können als Pflanzenteile, frisch oder getrocknet, Blätter, Stammrinde oder Wurzelstock eingesetzt werden.According to the invention, leaves, stem bark or rhizome can be used as plant parts, fresh or dried.
Das organische Extraktionsmittel ist insbesondere Methanol, Ethanol, Propa- nol, Aceton, Ethylacetat oder Gemische daraus mit Wasser, Dichlormethan und/oder überkritisches Kohlendioxid.The organic extractant is in particular methanol, ethanol, propanol, acetone, ethyl acetate or mixtures thereof with water, dichloromethane and / or supercritical carbon dioxide.
Die Behandlung unter basischen oder sauren Bedingungen erfolgt insbesondere mittels Natron- und Kalklauge oder mittels Mineralsäuren wie Schwefelsäure oder Salzsäure. Diese Behandlung führt vorteilhafterweise zur Abreicherung von Alkaloiden.The treatment under basic or acidic conditions is carried out in particular using sodium hydroxide and lime liquor or using mineral acids such as sulfuric acid or hydrochloric acid. This treatment advantageously leads to the depletion of alkaloids.
Die genannte Behandlung unter basischen oder sauren Bedingungen wird vorzugsweise bei Bedingungen durchgeführt, bei denen der Wassergehalt mehr als 50 Vol.-%, vorzugsweise mehr als 70 Vol.-% der Lösung beträgt. Für eine Behandlung unter basischen Bedingungen sollte der pH-Wert 9 oder mehr betragen, bevorzugt 10 oder mehr. In einer Ausführungsform der Erfindung kann der pH-Wert auch 11 oder mehr betragen. Besonders geeignete Bereiche sind pH 9 bis 11.Said treatment under basic or acidic conditions is preferably carried out under conditions in which the water content is more than 50% by volume, preferably more than 70% by volume, of the solution. For treatment under basic conditions, the pH should be 9 or more, preferably 10 or more. In one embodiment of the invention, the pH can also be 11 or more. Particularly suitable ranges are pH 9 to 11.
Bei einer Behandlung unter sauren Bedingungen soll der pH-Wert vorzugswei- se 3 oder weniger, bevorzugt 2,5 oder weniger betragen. In einer bevorzugten Ausführungsform kann er auch 2 oder weniger betragen. Besonders geeignete Bereiche sind pH 3 bis pH 1,5.In the case of treatment under acidic conditions, the pH should preferably be 3 or less, preferably 2.5 or less. In a preferred embodiment, it can also be 2 or less. Particularly suitable ranges are pH 3 to pH 1.5.
Die Behandlung wird typischerweise für einen Zeitraum von 5 min bis 12 Stunden durchgeführt, mehr bevorzugt zwischen 0,5 und 6 Stunden, noch mehr bevorzugt zwischen 1 und 4 Stunden. Dabei kann die Behandlung auch bei etwas erhöhter Temperatur erfolgen. Besonders geeignete Bedingungen für die Behandlung sind Temperaturen zwischen 0 und 80°C, mehr bevorzugt zwischen Raumtemperatur und 50°C. Alkaloide und/oder andere Stoffe können auch durch Adsorptionsprozesse an Adsorbentien zum Beispiel an Kationenaustauschern oder organischen Polymerharzen (z.B. Amberlite XAD) abgetrennt werden. Als Alternative oder zusätzlicher Schritt kommt auch eine Flüssig-Flüssig-Extraktion in Betracht.The treatment is typically carried out for a period of 5 minutes to 12 hours, more preferably between 0.5 and 6 hours, even more preferably between 1 and 4 hours. The treatment can also be carried out at a somewhat elevated temperature. Particularly suitable conditions for the treatment are temperatures between 0 and 80 ° C, more preferably between room temperature and 50 ° C. Alkaloids and / or other substances can also be separated off by adsorption processes on adsorbents, for example on cation exchangers or organic polymer resins (for example Amberlite XAD). Liquid-liquid extraction is also an alternative or additional step.
Bei einer Flüssig-Flüssig-Extraktion wird der Extrakt in wässriger Lösung mit einem organischen Lösungsmittel extrahiert. Typische geeignete Lösungsmittel sind Butanol und Ethylacetat.In the case of liquid-liquid extraction, the extract is extracted in aqueous solution with an organic solvent. Typical suitable solvents are butanol and ethyl acetate.
Selbstverständlich können die Abreicherungsschritte nicht nur einzeln, sondern auch in Kombination und in beliebiger Reihenfolge durchgeführt werden.The depletion steps can of course not only be carried out individually, but also in combination and in any order.
Ein geeignetes Verfahren ist z.B. die Behandlung mit einem Kationenaustauscher in saurer (H+) Form. Hierdurch wird gleichzeitig der pH-Wert abgesenkt und zusätzlich eine Adsorption an Kationenaustauschern ermöglicht.A suitable method is, for example, treatment with a cation exchanger in acid (H + ) form. This simultaneously lowers the pH and also enables adsorption on cation exchangers.
Gegenstand der Erfindung ist auch ein Pflanzenextrakt erhältlich nach dem erfindungsgemäßen Verfahren. Die erfindungsgemäße Extrakte enthalten die Kavapyrone, die zumeist chemische Derivate des Kavain (5,6-Dihydroxy-4- methoxy-6-styryl-2H-pyran-2-on) darstellen.The invention also relates to a plant extract obtainable by the process according to the invention. The extracts according to the invention contain the kavapyrones, which are mostly chemical derivatives of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one).
Möglicherweise beruht der Effekt des erfindungsgemäßen Verfahrens auf der chemisch relativ verminderten Stabilität der Alkaloide, welche eine starke Hydrolysebereitschaft der strukturell als Amidalkaloide aufzufassenden In- haltsstoffe zu besitzen scheinen. Forciert werden kann diese Zersetzung beispielsweise durch eine basische oder saure Verseifung. Bei dieser Hydrolyse werden aus den Alkaloiden eine Amino- und eine Säurekomponente freigesetzt, die weniger schädlich sein sollte, oder aber durch geeignete Adsorber, wie Ionenaustauschern, eliminiert werden können.The effect of the method according to the invention may be based on the chemically relatively reduced stability of the alkaloids, which seem to be very susceptible to hydrolysis of the constituents to be structurally regarded as amide alkaloids. This decomposition can be forced, for example, by basic or acidic saponification. During this hydrolysis, an amino and an acid component are released from the alkaloids, which should be less harmful or can be eliminated by suitable adsorbers, such as ion exchangers.
Hinsichtlich einer physikalischen Instabilität der Alkaloide konnte eine thermische Labilität besonders in Gegenwart von Wasser beobachtet werden, die wahrscheinlich auch solvatolytisch manifestiert ist. Des weiteren können die obengenannten Alkaloide, wie auch ihre Hydrolyseprodukte basischen oder amphoteren Charakter aufweisen. Starke Affinität zu geladenen Adsorbem konnte gefunden werden. Solche Adsorber sind zugleich sehr gut geeignete Hydrolysekatalysatoren und daher bevorzugte Medien zur Abtrennung der Alkaloidspuren.With regard to the physical instability of the alkaloids, thermal lability was observed, especially in the presence of water, which is probably also manifested solvatolytically. Furthermore, the above-mentioned alkaloids, like their hydrolysis products, can have a basic or amphoteric character. Strong affinity for charged adsorbents was found. Such adsorbers are also very suitable hydrolysis catalysts and therefore preferred media for separating the alkaloid traces.
Der erfindungsgemäße Extrakt kann zur Herstellung von Arzneimitteln, Nah- rungsergänzungsmitteln, Veterinärprodukten oder Kosmetika in flüssigen oder festen Extraktzubereitungen verwendet werden.The extract according to the invention can be used for the production of medicaments, food supplements, veterinary products or cosmetics in liquid or solid extract preparations.
Beispiele:Examples:
Beispiel 1example 1
13,3 kg Kava -Wurzelstock, geschnitten und gesiebt zu Teilstücken von 6 bis 8 mm, werden mit 160 kg Ethanol 96% V/V bei 45°C über 24 h erschöpfend extrahiert. Die filtrierten, vereinigten ethanolischen Abläufe werden bei 55°C im Vakuum schonend zu einem pastösen Kava -Mutterextrakt beigedampft. Der resultierende Spissumextrakt von 1,1 kg hat einen Trockensubstanzanteil von 94% m/m. Dieser vom Auszugsmittel befreite Extrakt (Ethanol < 0,5% m/m) enthält 58 Gew.-% Kavapyrone (HPLC) und 69 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.13.3 kg of kava rhizomes, cut and sieved to pieces of 6 to 8 mm, are exhaustively extracted with 160 kg of ethanol 96% V / V at 45 ° C for 24 h. The filtered, combined ethanolic processes are gently evaporated at 55 ° C in a vacuum to a paste-like kava nut extract. The resulting spissum extract of 1.1 kg has a dry matter content of 94% m / m. This extract, which has been freed from the extractant (ethanol <0.5% m / m), contains 58% by weight Kavapyrone (HPLC) and 69 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
Beispiel 2Example 2
11,2 kg Kava-Peelings der Stammrinde werden analog Beispiel 1 bis zum pastösen Mutterextrakt hergestellt. Es resultieren 0,86 kg Spissumextrakt mit einem Trocken rückstand von 95% m/m. Der lösemittelfreie Extrakt enthält 51 Gew.-% Kavapyrone (HPLC) und 230 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.11.2 kg of kava peels of the trunk bark are produced analogously to Example 1 up to the pasty mother extract. The result is 0.86 kg of spissum extract with a dry residue of 95% m / m. The solvent-free extract contains 51% by weight Kavapyrone (HPLC) and 230 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
Beispiel 3Example 3
100 g des Kava-Spissumextraktes erhalten gemäß Beispiel 1 werden in Ethanol 80% V/V rückgelöst. Anschließend wird unter ständigem Rühren bei 55°C Produkttemperatur, soviel Schwefelsäure tropfenweise zugegeben, bis sich ein pH von ca. 3 einstellt. Nach 2 h Rührzeit wird die Extraktlösung auf Raumtemperatur abgekühlt und mit einer Laugenlösung neutralisiert. Ausgefallene Niederschläge werden abfiltriert und die Extraktlösung erneut zum Spissu- mextrakt beigedampft. Der Spissum enthält 54 Gew.-% Kavapyrone (HPLC) und 5 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. The mixture is then stirred at 55 ° C. Product temperature, so much sulfuric acid added dropwise until a pH of approx. 3 is reached. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are filtered off and the extract solution is evaporated down again to the spissumin extract. The spissum contains 54% by weight Kavapyrone (HPLC) and 5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
Beispiel 4Example 4
100 g des Kava-Spissumextraktes erhalten gemäß Beispiel 1 werden in Etha- nol 80% V/V rückgelöst. Anschließend wird unter ständigem Rühren bei Raumtemperatur, soviel Kalklauge tropfenweise zugegeben, bis sich ein pH von ca. 11 einstellt. Nach 2 h Rührzeit wird die Extraktlösung mit einer mineralischen Säurenlösung neutralisiert. Ausgefallene Niederschläge werden separiert und die Extraktlösung erneut zum Spissumextrakt beigedampft. Der Spissum ent- hält 49 Gew.-% Kavapyrone (HPLC) und < 5 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at room temperature, as much lime is added dropwise until a pH of approx. 11 is reached. After stirring for 2 hours, the extract solution is neutralized with a mineral acid solution. Precipitated precipitates are separated and the extract solution is evaporated again to the spissum extract. The spissum contains 49% by weight Kavapyrone (HPLC) and <5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
Beispiel 5Example 5
100 g des Kava-Spissumextraktes erhalten gemäß Beispiel 1 werden in Ethanol 80% V/V rückgelöst. Anschließend wird unter ständigem Rühren bei 55°C Produkttemperatur, soviel Schwefelsäure tropfenweise zugegeben, bis sich ein pH von ca. 3 einstellt. Nach 2 h Rührzeit wird die Extraktlösung auf Raumtemperatur abgekühlt und mit einer Laugenlösung neutralisiert. Ausgefallene Niederschläge werden separiert und die Extraktlösung wird durch zweifaches Ausrühren mit demselben Volumen an Ethylacetat in eine organische Phase überführt. Diese wird unter vermindertem Druck beigedampft. Der erhaltene Spissum enthält 62 Gew.-% Kavapyrone (HPLC) und < 5 ppm Alkaloid- Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt. Beispiel 6100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at 55 ° C product temperature, so much sulfuric acid is added dropwise until a pH of approx. 3 is established. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are separated and the extract solution is converted into an organic phase by stirring twice with the same volume of ethyl acetate. This is evaporated under reduced pressure. The spissum obtained contains 62% by weight of Kavapyrone (HPLC) and <5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract. Example 6
100 g des Kava-Spissumextraktes erhalten gemäß Beispiel 2 werden in schwefelsaurem Wasser bei pH 1-2 unter starkem Rühren bei 40°C für 1 h suspendiert. Anschließend wird die sich abtrennende wässrige Phase entfernt. Der Extrakt wird in Ethanol 80% (V/V) rückgelöst und über einen Kationenaustauscher geleitet. Die durchlaufenden wässrig-ethanolischen Eluate werden anschließend unter vermindertem Druck beigedampft. Der erhaltene Spissum enthält 47 Gew.-% Kavapyrone (HPLC) und < 5 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.100 g of the kava spissum extract obtained according to Example 2 are suspended in sulfuric acid water at pH 1-2 with vigorous stirring at 40 ° C. for 1 h. The aqueous phase that separates is then removed. The extract is redissolved in ethanol 80% (V / V) and passed over a cation exchanger. The continuous aqueous-ethanolic eluates are then evaporated under reduced pressure. The spissum obtained contains 47% by weight of Kavapyrone (HPLC) and <5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract.
Beispiel 7Example 7
10 kg Kava -Wurzelstock, geschnitten und gesiebt zu Teilstücken von 6 bis 8 mm, werden mit 180 kg Aceton (60% m/m) bei 35°C über 24h erschöpfend extrahiert. Die filtrierten, vereinigten acetonischen Abläufe werden bei 40°C im Vakuum schonend zu einem pastösen Kava-Mutterextrakt beigedampft. Der resultierende Spissumextrakt von 1,2 kg hat einen Trockensubstanzanteil von 88% m/m. Dieser vom Auszugsmittel befreite Extrakt enthält 54 Gew.-% Kavapyrone (HPLC) und 86 ppm Alkaloid-Verbindungen ber. als Pipermethystin (GC), jeweils bezogen auf den Trockenextrakt.10 kg kava rhizome, cut and sieved to pieces of 6 to 8 mm, are exhaustively extracted with 180 kg acetone (60% m / m) at 35 ° C for 24 hours. The filtered, combined acetone processes are gently evaporated at 40 ° C in a vacuum to a pasty kava mother extract. The resulting spissum extract of 1.2 kg has a dry matter content of 88% m / m. This extract, which is freed from the extracting agent, contains 54% by weight of Kavapyrone (HPLC) and 86 ppm of alkaloid compounds, calculated as pipermethystin (GC), in each case based on the dry extract.
Zur Entfernung der Alkaloid-Anteile wird der Extrakt in Ethanol 70% V/V rück- gelöst und über einen stark sauren Kationenaustauscher (Sulfonsäure-Harz) in Form einer gepackten Säule geleitet. Das nach Säulendurchlauf erhaltene Eluat wird im Vakuum zu Spissum bei 55°C eingedampft. Dieser Extrakt enthält unverändert einen hohen Anteil von 52 Gew.-% Kavapyronen und ist praktisch frei von Alkaloidverbindungen (< 5 ppm), jeweils bezogen auf den Trockenextrakt. To remove the alkaloid, the extract is redissolved in 70% v / v ethanol and passed through a strongly acidic cation exchanger (sulfonic acid resin) in the form of a packed column. The eluate obtained after passage through the column is evaporated in vacuo to spissum at 55 ° C. This extract still contains a high proportion of 52% by weight of kavapyrones and is practically free of alkaloid compounds (<5 ppm), based in each case on the dry extract.

Claims

Patentansprüche claims
1. Verfahren zur Herstellung eines Pflanzenextraktes von Kava (Piper methysticum) mit folgenden Schritten:1. A method for producing a plant extract of kava (Piper methysticum) with the following steps:
- Extraktion von Pflanzenteilen mit organischen Extraktionsmitteln wie wasserhaltigen oder wasserfreien freien Alkoholen, Ketonen, Carbonsäureestern, Alkanen, chlorierten Kohlenwasserstoffen sowie überkritischen Gasen oder Gemischen daraus, sowie- Extraction of parts of plants with organic extraction agents such as water-containing or anhydrous free alcohols, ketones, carboxylic acid esters, alkanes, chlorinated hydrocarbons and supercritical gases or mixtures thereof, and
- Behandlung des von organischen Extraktionsmitteln zumindest teilweise befreiten Rückstandes unter sauren (pH < 3) oder basischen (pH > 9) Bedingungen und/oder- Treatment of the residue at least partially freed from organic extracting agents under acidic (pH <3) or basic (pH> 9) conditions and / or
- Adsorptionsprozessen an Kationenaustauschern oder ungeladenen Ad- sorbentien auf Basis organischen Polymerharzen.- Adsorption processes on cation exchangers or uncharged adsorbents based on organic polymer resins.
2. Verfahren nach Anspruch 1, wobei die verwendeten Pflanzenteile, frisch oder getrocknet, Blätter, Stammrinde oder Wurzelstock sind.2. The method according to claim 1, wherein the plant parts used, fresh or dried, are leaves, trunk bark or rhizome.
3. Verfahren nach Anspruch 1 und/oder 2, wobei das organische Extraktionsmittel Methanol, Ethanol, Propanol, Aceton, Ethylacetat oder Gemischen daraus mit Wasser, Dichlormethan und/oder überkritisches Kohlendioxid ist.3. The method according to claim 1 and / or 2, wherein the organic extractant is methanol, ethanol, propanol, acetone, ethyl acetate or mixtures thereof with water, dichloromethane and / or supercritical carbon dioxide.
4. Verfahren nach mindestens einem der Ansprüche 1 bis 3, wobei die Be- handlung unter basischen Bedingungen mittels Natron- und Kalklauge erfolgt.4. The method according to at least one of claims 1 to 3, wherein the treatment is carried out under basic conditions by means of sodium hydroxide and lime.
5. Verfahren nach mindestens einem der Ansprüche 1 bis 4, wobei die Behandlung unter sauren Bedingungen mittels Mineralsäuren wie Salzsäure oder Schwefelsäure erfolgt.5. The method according to at least one of claims 1 to 4, wherein the treatment is carried out under acidic conditions using mineral acids such as hydrochloric acid or sulfuric acid.
6. Verfahren nach mindestens einem der Ansprüche 1 bis 5, wobei die Adsorptionsprozesse durch eine Flüssig-Flüssig-Extraktion ersetzt ist. 6. The method according to at least one of claims 1 to 5, wherein the adsorption processes is replaced by a liquid-liquid extraction.
7. Pflanzenextrakt erhältlich gemäß einem Verfahren nach mindestens einem der Ansprüche 1 bis 6.7. Plant extract obtainable according to a process according to at least one of claims 1 to 6.
8. Verwendung des Extrakts gemäß Anspruch 7 zur Herstellung von Arzneimitteln, Nahrungsergänzungsmitteln, Veterinärprodukten oder Kosmetika in flüssigen oder festen Extraktzubereitungen. 8. Use of the extract according to claim 7 for the production of medicaments, food supplements, veterinary products or cosmetics in liquid or solid extract preparations.
EP04786236A 2003-08-27 2004-08-26 Alkaloid-reduced kava extract Withdrawn EP1663272A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04786236A EP1663272A1 (en) 2003-08-27 2004-08-26 Alkaloid-reduced kava extract

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03019343 2003-08-27
PCT/EP2004/051920 WO2005021017A1 (en) 2003-08-27 2004-08-26 Alkaloid-reduced kava extract
EP04786236A EP1663272A1 (en) 2003-08-27 2004-08-26 Alkaloid-reduced kava extract

Publications (1)

Publication Number Publication Date
EP1663272A1 true EP1663272A1 (en) 2006-06-07

Family

ID=34259140

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04786236A Withdrawn EP1663272A1 (en) 2003-08-27 2004-08-26 Alkaloid-reduced kava extract

Country Status (2)

Country Link
EP (1) EP1663272A1 (en)
WO (1) WO2005021017A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920790A (en) * 2012-11-12 2013-02-13 沈阳药科大学 Application of pepper extractives in preparation of sedative hypnotic medicines or health foods
CN117964831B (en) * 2024-03-29 2024-08-16 广州伽能生物科技有限公司 Preparation method and application of kavain temperature-sensitive molecularly imprinted polymer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5842686A (en) * 1981-09-08 1983-03-12 T Hasegawa Co Ltd Extraction of anti-oxidizing component in natural pepper
DE4028945A1 (en) * 1990-09-12 1992-03-19 Schwabe Willmar Gmbh & Co KAWA-KAWA EXTRACT, METHOD FOR PRODUCING IT AND ITS USE
DE4401646A1 (en) * 1994-01-21 1995-07-27 Krewel Werke Gmbh Optimally releasing kava extracts
EP0987026A1 (en) * 1998-08-21 2000-03-22 Max Zeller Söhne AG Process of preparation of a Kawa-Kawa Extract
GB2385289A (en) * 2002-01-18 2003-08-20 Advanced Phytonics Ltd Purifying a material using a non-aqueous solvent and an ion exchange resin or adsorbent.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005021017A1 *

Also Published As

Publication number Publication date
WO2005021017A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
DE3940092C2 (en)
DE102014202318B4 (en) Improved process for the production of ginkgo extracts
DE69031481T2 (en) Process for the extraction of ginkgo leaves from ginkgo leaves and their purification
EP0692257A1 (en) Process of preparation of poor pesticide active principles concentrates from plants
EP2493337B1 (en) Method for producing a carnosic acid-rich plant extract
EP0702957A1 (en) Extracts of St.John&#39;s wort
EP0382116B1 (en) Process for removing pesticides from ginseng root
EP0874550B1 (en) Extraction of substances from components of the neem tree
EP1663272A1 (en) Alkaloid-reduced kava extract
DE2656602C3 (en) Method for extracting 2-hydroxymethyl-3,4,5-trihydroxypiperidine from mulberry plants
EP1391208A1 (en) Process of preparation of plant extracts with high isoflavone content
EP0508330B1 (en) Rhizoma petasitidis extraction process with carbon dioxide
DE60108272T2 (en) PHARMACEUTICAL COMPOSITION CONTAINING (-) - SECOISOLARICINESINOL
DE4002938A1 (en) Prepn. of extracts of rhizoma petasitidis - by extraction with compressed carbon di:oxide and subsequent sepn. of the extract by reducing the density
AT392970B (en) METHOD FOR OBTAINING A PRIMARY PENTACYCLIC OXINDOL ALKALOID MIXTURE
DE102009040381A1 (en) Process for the isolation of alkaloids from plants
DE10014670B4 (en) Process for the extraction and isolation of Santonin from Artemisia sp.
DE2609533A1 (en) PROCESS FOR EXTRACTION OF ACTIVE SUBSTANCES, IN PARTICULAR OF HETEROSIDE EAST, COFFEE ACID, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE1617469C3 (en) Process for obtaining a basic ingredient from Cabucala madagascariensis
EP0665231A1 (en) Process for obtaining oxindole alkaloids
DE2259388C3 (en) Method of obtaining vincristine
DE102006019863A1 (en) Preparation of Ginkgo biloba extract used for treating e.g. dementia or cerebral disorder, involves extracting aqueous alcoholic solution of Ginkgo biloba leaves with heptane to remove alkyl phenol compounds
DE1117593B (en) Process for the production of alkaloid mixtures from Rauwolfia plants
DE1617469B2 (en) PROCESS FOR OBTAINING A BASIC INGREDIENT FROM CABUCALA MADAGASCARIENSIS
DE2432266A1 (en) Two naturally occuring hypotensive agents - extd. from Cadia ellisiana after removal of fats and septd. by chromatography

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080709